BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 18483389)

  • 1. Molecular characterization of pediatric gastrointestinal stromal tumors.
    Agaram NP; Laquaglia MP; Ustun B; Guo T; Wong GC; Socci ND; Maki RG; DeMatteo RP; Besmer P; Antonescu CR
    Clin Cancer Res; 2008 May; 14(10):3204-15. PubMed ID: 18483389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
    Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.
    Prakash S; Sarran L; Socci N; DeMatteo RP; Eisenstat J; Greco AM; Maki RG; Wexler LH; LaQuaglia MP; Besmer P; Antonescu CR
    J Pediatr Hematol Oncol; 2005 Apr; 27(4):179-87. PubMed ID: 15838387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of an Italian series of sporadic GISTs.
    Origone P; Gargiulo S; Mastracci L; Ballestrero A; Battistuzzi L; Casella C; Comandini D; Cusano R; Dei Tos AP; Fiocca R; Garuti A; Ghiorzo P; Martinuzzi C; Toffolatti L; ; Bianchi Scarrà G
    Gastric Cancer; 2013 Oct; 16(4):596-601. PubMed ID: 23291969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors.
    Italiano A; Chen CL; Sung YS; Singer S; DeMatteo RP; LaQuaglia MP; Besmer P; Socci N; Antonescu CR
    BMC Cancer; 2012 Sep; 12():408. PubMed ID: 22974104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
    Bombac A; Zakotnik B; Bucic M; Setrajcic Dragos V; Gazic B; Stegel V; Klancar G; Novakovic S
    Int J Oncol; 2020 Jun; 56(6):1468-1478. PubMed ID: 32236636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
    J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
    Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
    Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
    He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
    Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.
    Huss S; Elges S; Trautmann M; Sperveslage J; Hartmann W; Wardelmann E
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):623-8. PubMed ID: 25831232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.